Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of dichloroacetate in the treatment of genetic mitochondrial diseases.

Advanced drug delivery reviews - 1 Jan 2000

Stacpoole Peter W, Kurtz Tracie L, Han Zongchao, Langaee Taimour

Abstract excerpt

Dichloroacetate (DCA) is an investigational drug for the treatment of genetic mitochondrial diseases. Its primary site of action is the pyruvate dehydrogenase (PDH) complex, which it stimulates by altering its phosphorylation state and stability. DCA is metabolized by and inhibits the bifunctional zeta-1 family isoform of glutathione transferase/maleylacetoacetate isomerase. Polymorphic variants of this enzyme...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aging
Share to cis-trans-Isomerases
Share to Glutathione Transferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isoenzymes

Share to Mitochondrial Diseases

Share to Pyruvate Dehydrogenase Complex

Share to Pyruvate Dehydrogenase Complex Deficiency Disease

Share to Randomized Controlled Trials as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 18647626
DOI: 10.1016/j.addr.2008.02.014
PMCID: PMC3746325

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of dichloroacetate in the treatment of genetic mitochondrial diseases.PMID 18647626Read ↗

Pharmacogenetic considerations with dichloroacetate dosing.Semantic proximity Read ↗

Therapeutic potential of dichloroacetate for pyruvate dehydrogenase complex deficiency.Semantic proximity Read ↗

Haplotype variations in glutathione transferase zeta 1 influence the kinetics and dynamics of chronic dichloroacetate in children.Semantic proximity Read ↗

Personalized Dosing of Dichloroacetate Using GSTZ1 Clinical Genotyping Assay.Semantic proximity Read ↗

Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate.Semantic proximity Read ↗

Dichloroacetate treatment in Leigh syndrome caused by mitochondrial DNA mutation.Semantic proximity Read ↗

Pivotal role of the C-terminal DW-motif in mediating inhibition of pyruvate dehydrogenase kinase 2 by dichloroacetate.Semantic proximity Read ↗

Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation.Semantic proximity Read ↗

Prenatal and postnatal expression of glutathione transferase ζ 1 in human liver and the roles of haplotype and subject age in determining activity with dichloroacetate.Semantic proximity Read ↗

Age-Related Changes in Expression and Activity of Human Hepatic Mitochondrial Glutathione Transferase Zeta1.Semantic proximity Read ↗

Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients.Semantic proximity Read ↗

Differential phenotypic expression of a novel PDHA1 mutation in a female monozygotic twin pair.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.